76
|
Spicer RA, Sengupta S, Phillips L. Low temperature preparation of pteridophyte spores and sporangia for SEM. J Microsc 2011. [DOI: 10.1111/j.1365-2818.1976.tb02416.x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
77
|
Chlebowski RT, McTiernan A, Aragaki AK, Rohan T, Wactawski-Wende J, Ipp E, Euhus D, Kaklamani VG, Vitolins M, Wallace RB, Liu S, Gunter MJ, Phillips L, Strickler H, Howard B. Metformin and breast cancer incidence in postmenopausal diabetic women in the Women’s Health Initiative (WHI). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.1503] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
78
|
Mitra B, Phillips L, Cameron PA, Billah B, Reid C. The safety of recombinant factor VIIa in cardiac surgery. Anaesth Intensive Care 2010; 38:671-7. [PMID: 20715730 DOI: 10.1177/0310057x1003800409] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
We investigated whether there was an association between recombinant activated factor VII (rFVIIa) use in cardiac surgery and thromboembolic events by comparing cases in two medical registries. The incidence of thromboembolic events in patients undergoing cardiac surgery (except isolated coronary artery bypass grafts) who had received rFVIIa and were entered into the Australian and New Zealand Haemostasis Registry was compared with the background incidence in patients entered in the Australasian Society for Cardiac and Thoracic Surgeons database. Mortality, length of hospital stay and thromboembolic complications such as stroke, perioperative myocardial infarction and pulmonary embolism data were analysed. A total of 705 patients in the Registry were compared with 6554 patients in the Thoracic Surgeons database. The use of rFVIIa was independently associated with higher mortality (odds ratio 2.55, P < 0.001) and longer hospital stay (odds ratio 1.54, P = 0.020). However multiple regression analyses showed no independent association between rFVIIa and stroke (odds ratio 1.0, P = 0.994) or perioperative myocardial infarction (odds ratio 0.29, P = 0.053), while the use of rFVIIa was associated with fewer pulmonary emboli (odds ratio 0.02, P < 0.001). These findings indicate that patients who received rFVIIa had increased mortality and length of hospital stay, as expected, but that rFVIIa use was not associated with an increased incidence of stroke or perioperative myocardial infarction. In the absence of randomised controlled clinical trials, this analysis suggests that the off-label use of rFVIIa in cardiac surgery does not significantly increase thromboembolic events.
Collapse
|
79
|
Interrante V, Phillips L, Ries B, Kaeding M. Investigating the potential impact of presence on the accuracy of participants' distance judgments in photo-realistic and non-photorealistic immersive virtual environments. J Vis 2010. [DOI: 10.1167/10.7.1038] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
80
|
Aglitskiy Y, Velikovich AL, Karasik M, Metzler N, Zalesak ST, Schmitt AJ, Phillips L, Gardner JH, Serlin V, Weaver JL, Obenschain SP. Basic hydrodynamics of Richtmyer-Meshkov-type growth and oscillations in the inertial confinement fusion-relevant conditions. PHILOSOPHICAL TRANSACTIONS. SERIES A, MATHEMATICAL, PHYSICAL, AND ENGINEERING SCIENCES 2010; 368:1739-1768. [PMID: 20211882 DOI: 10.1098/rsta.2009.0131] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
In inertial confinement fusion (ICF), the possibility of ignition or high energy gain is largely determined by our ability to control the Rayleigh-Taylor (RT) instability growth in the target. The exponentially amplified RT perturbation eigenmodes are formed from all sources of the target and radiation non-uniformity in a process called seeding. This process involves a variety of physical mechanisms that are somewhat similar to the classical Richtmyer-Meshkov (RM) instability (in particular, most of them are active in the absence of acceleration), but differ from it in many ways. In the last decade, radiographic diagnostic techniques have been developed that made direct observations of the RM-type effects in the ICF-relevant conditions possible. New experiments stimulated the advancement of the theory of the RM-type processes. The progress in the experimental and theoretical studies of such phenomena as ablative RM instability, re-shock of the RM-unstable interface, feedout and perturbation development associated with impulsive loading is reviewed.
Collapse
|
81
|
Menneer T, Barrett DJ, Phillips L, Donnelly N, Cave KR. The breakdown of efficient search when either of two colour targets can appear. J Vis 2010. [DOI: 10.1167/3.9.568] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
82
|
Phillips L. Automating referrals aids discharge processes. Software-as-a-service model sends data electronically to multiple facilities, easing case-management staff workload. HEALTH MANAGEMENT TECHNOLOGY 2010; 31:24-25. [PMID: 20405758] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/29/2023]
|
83
|
Willis C, Bird R, Mullany D, Cameron P, Phillips L. Use of rFVIIa for critical bleeding in cardiac surgery: dose variation and patient outcomes. Vox Sang 2009; 98:531-7. [PMID: 19878495 DOI: 10.1111/j.1423-0410.2009.01276.x] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
BACKGROUND AND OBJECTIVES Recombinant activated factor VIIa (rFVIIa) is increasingly being used in non-haemophiliac patients for the treatment of severe bleeding refractory to standard interventions. Optimal dosing regimens remain debated in cardiac surgery. Therefore, this study investigated the use of different rFVIIa dosing practices on response to bleeding and patient outcomes in cardiac surgery patients using data from the Haemostasis Registry. METHODS Data were extracted from the Haemostasis Registry that records cases of off-licence rFVIIa use in participating institutions. Univariate analyses compared patients receiving < or =40 microg/kg, 41-60 microg/kg, 61-80 microg/kg, 81-100 microg/kg and >100 microg/kg of rFVIIa on key parameters. Logistic regression models investigated the relationship between independent variables and 28-day mortality. RESULTS Complete data was available on 804 cardiac surgery patients who received rFVIIa. Of these, 42 (5.2%) were treated with doses < or =40 microg/kg, while the dose group containing the most patients was 81-100 microg/kg (368, 45.77%). Results demonstrated no significant differences in the rate of thromboembolic adverse events, response to bleeding or 28-day mortality. CONCLUSIONS These findings raise the important question of whether lower doses of rFVIIa may be as effective as higher doses in the treatment of severe bleeding in cardiac surgery patients.
Collapse
|
84
|
Willis CD, Cameron PA, Phillips L. Variation in the use of recombinant activated factor VII in critical bleeding. Intern Med J 2009; 40:486-93. [PMID: 19712199 DOI: 10.1111/j.1445-5994.2009.02044.x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
BACKGROUND Recombinant activated factor VII (rFVIIa) is being increasingly used as a treatment option in settings of uncontrolled bleeding. Despite this, national practice guidelines are lacking, resulting in widespread practice variation between providers. This investigation aimed to describe the differences in use of rFVIIa across Australian and New Zealand hospitals. METHODS Data were extracted from the Haemostasis Registry that collects both contemporaneous and retrospective cases of off-licence (i.e. in non-haemophilia patients) rFVIIa use in participating institutions. Hospitals were classified according to geographical location and service provision. RESULTS 2075 cases from 87 hospitals were recorded on the Haemostasis Registry. Across all hospital categories, over 41% of cases received rFVIIa in relation to cardiac surgery. Case complexity varied between providers, with large urban centres treating more severely ill patients. This was reflected in significant differences in the use of blood components and products before rFVIIa administration. Despite differences in patient complexity and use of blood products between hospital categories, response to treatment and patient outcomes remained similar across providers, with survival rates ranging from 68.29% to 70.41%. CONCLUSION This is the largest study of off-licence use of rFVIIa. There is significant regional variation in the administration of rFVIIa in Australian and New Zealand hospitals, with little documentation of adherence to guidelines. National consensus guidelines based on available evidence should be developed and promulgated to ensure optimal outcomes.
Collapse
|
85
|
Phillips L, Toledo AH, Lopez-Neblina F, Anaya-Prado R, Toledo-Pereyra LH. Nitric oxide mechanism of protection in ischemia and reperfusion injury. J INVEST SURG 2009; 22:46-55. [PMID: 19191157 DOI: 10.1080/08941930802709470] [Citation(s) in RCA: 126] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
In 1992 nitric oxide (NO) was declared molecule of the year by Science magazine, and ever since research on this molecule continues to increase. Following this award, NO was shown to be a mediator/protector of ischemia and reperfusion injury in many organs, such as the heart, liver, lungs, and kidneys. Controversy has existed concerning the actual protective effects of NO. However, literature from the past 15 years seems to reinforce the consensus that NO is indeed protective. Some of the protective actions of NO in ischemia and reperfusion are due to its potential as an antioxidant and anti-inflammatory agent, along with its beneficial effects on cell signaling and inhibition of nuclear proteins, such as NF-kappa B and AP-1. New therapeutic potentials for this drug are also continuously emerging. Exogenous NO and endogenous NO may both play protective roles during ischemia and reperfusion injury. Sodium nitroprusside and nitroglycerin have been used clinically with much success; though only recently have they been tested and proven effective in attenuating some of the injuries associated with ischemia and reperfusion. NO inhalation has, in the past, mostly been used for its pulmonary effects, but has also recently been shown to be protective in other organs. The potential of NO in the treatment of ischemic disease is only just being realized. Elucidation of the mechanism by which NO exerts its protective effects needs further investigation. Therefore, this paper will focus on the mechanistic actions of NO in ischemia and reperfusion injury, along with the compound's potential therapeutic benefits.
Collapse
|
86
|
Yunger S, Douglas P, Anglin P, Crump M, Lepage S, Shum D, Phillips L, Milliken D. Patient out-of-pocket and insurer payment decisions for bevacizumab for metastatic colorectal cancer: A Canadian analysis. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.6576] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
6576 Background: Like many health care services in Canada, intravenous (IV) cancer therapies are typically funded publicly through hospitals and provincial cancer agencies. Delays may be encountered between regulatory approval and public funding of new drugs. IV drugs are not routinely covered through private insurance (PRI) plans, requiring patients to appeal for special consideration, including employer exceptions or pay cash. Uncertainty of drug funding may create challenges for physicians and patients when discussing treatment options. The Roche Patient Assistance Program (RPAP) provides reimbursement navigation, copay/financial assistance and access to infusion clinics. This observational study examines patient access to bevacizumab (B) in the absence of public funding. Methods: An analysis of the RPAP database for the period of July 2006 to August 2008 was conducted assessing patients enrolled, insurance status, approval rates, and access to B. Receipt of treatment with B was evaluated according to insurance coverage. Results: A total of 877 patients accessed the RPAP for treatment with B. 647 (74%) had PRI and 230 (26%) were uninsured. Of PRI patients, 310 (48%) were approved coverage and 337 (52%) were denied. 204 patients (65%) with approved PRI coverage received B therapy. Of patients with PRI but denied coverage for B, 135 (40%) elected to pay for B. Of patients with no PRI, 120 (52%) paid for B. Of all patients with no coverage for B (no PRI or denied PRI), 255 patients (45%) elected to pay for B. Conclusions: In a public healthcare environment, when B was not publicly funded, approximately half of patients without any PRI coverage who accessed the RPAP were willing to pay for B. Although private insurers state IV drugs are not plan benefits, almost half of patients were able to obtain B coverage. A conventional analysis of willingness-to-pay should be conducted to better understand reasons behind patient and private insurer decisions observed in this study. Further research should also be conducted to determine whether results can be generalized to other unfunded anticancer agents within the Canadian health care system. [Table: see text]
Collapse
|
87
|
Stevens JE, Russo A, Maddox AF, Rayner CK, Phillips L, Talley NJ, Giguère M, Horowitz M, Jones KL. Effect of itopride on gastric emptying in longstanding diabetes mellitus. Neurogastroenterol Motil 2008; 20:456-63. [PMID: 18179609 DOI: 10.1111/j.1365-2982.2007.01058.x] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Delayed gastric emptying (GE) occurs in 30-50% of patients with longstanding type 1 or 2 diabetes, and represents a major cause of morbidity. Current therapeutic options are limited. We aimed at evaluating the effects of itopride on GE in patients with longstanding diabetes. Twenty-five patients (20 type 1, 5 type 2; 10 males, 15 females; mean age 45.2 +/- 2.7 years; body mass index 27.5 +/- 0.9 kg m(-2); duration of diabetes 20.2 +/- 2.4 years) were enrolled in a double-blind, placebo-controlled, randomized, crossover trial. Subjects received both itopride (200 mg) and placebo t.i.d. for 7 days, with a washout of 7-14 days. GE (scintigraphy), blood glucose (glucometer) and upper gastrointestinal (GI) symptoms (questionnaire) were measured following each treatment period. The test meal comprised 100 g ground beef (99mTc-sulphur colloid) and 150 mL of 10% dextrose [67Ga-ethylenediaminetetraacetic acid (EDTA)]. There was a slight trend for itopride to accelerate both solid (P = 0.09) and liquid (P = 0.09) GE. With itopride treatment, the emptying of both solids and liquids tended to be more accelerated, as the emptying with placebo was slower (solids: r = 0.39, P = 0.057; liquids: r = 0.44, P < 0.03). Twelve (48%) patients had delayed solid and/or liquid GE on placebo and in this group, itopride modestly accelerated liquid (P < 0.05), but not solid (P = 0.39), emptying. Itopride had no effect on mean blood glucose during the GE measurement (placebo: 9.8 +/- 0.6 mmol L(-1) vs itopride: 9.6 +/-0.6 mmol L(-1)), or GI symptoms (placebo: 1.4 +/- 0.4 vs itopride: 1.8 +/- 0.5). Itopride, in a dose of 200 mg t.i.d. for 7 days, tends to accelerate GE of liquids and solids in longstanding diabetes. The magnitude of this effect appears to be modest and possibly dependent on the rate of GE without itopride.
Collapse
|
88
|
Lebel C, Walker L, Leemans A, Phillips L, Beaulieu C. Microstructural maturation of the human brain from childhood to adulthood. Neuroimage 2008; 40:1044-55. [PMID: 18295509 DOI: 10.1016/j.neuroimage.2007.12.053] [Citation(s) in RCA: 985] [Impact Index Per Article: 61.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2007] [Revised: 09/14/2007] [Accepted: 12/23/2007] [Indexed: 12/11/2022] Open
Abstract
Brain maturation is a complex process that continues well beyond infancy, and adolescence is thought to be a key period of brain rewiring. To assess structural brain maturation from childhood to adulthood, we charted brain development in subjects aged 5 to 30 years using diffusion tensor magnetic resonance imaging, a novel brain imaging technique that is sensitive to axonal packing and myelination and is particularly adept at virtually extracting white matter connections. Age-related changes were seen in major white matter tracts, deep gray matter, and subcortical white matter, in our large (n=202), age-distributed sample. These diffusion changes followed an exponential pattern of maturation with considerable regional variation. Differences observed in developmental timing suggest a pattern of maturation in which areas with fronto-temporal connections develop more slowly than other regions. These in vivo results expand upon previous postmortem and imaging studies and provide quantitative measures indicative of the progression and magnitude of regional human brain maturation.
Collapse
|
89
|
Isbister J, Dunkley S, Cameron P, Phillips L. The Australasian haemostasis register for clinical use of recombinant activated factor VII. ACTA ACUST UNITED AC 2007. [DOI: 10.1111/j.1751-2824.2007.00123.x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
90
|
Isbister J, Phillips L, Dunkley S, Jankelowitz G, McNeil J, Cameron P. Recombinant activated factor VII in critical bleeding: experience from the Australian and New Zealand Haemostasis Register. Intern Med J 2007; 38:156-65. [DOI: 10.1111/j.1445-5994.2007.01472.x] [Citation(s) in RCA: 50] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
91
|
Phillips L, McCann E. The subjective experiences of people who regularly receive depot neuroleptic medication in the community. J Psychiatr Ment Health Nurs 2007; 14:578-86. [PMID: 17718731 DOI: 10.1111/j.1365-2850.2007.01145.x] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Little has been written on the subjective experiences of people who receive depot injections in the community. The authors of this paper have identified distinct gaps in the literature in terms of the views of service users regarding this particular intervention. Existing studies tend to focus upon the side effects of depot neuroleptic medication and the attitudes of Community Mental Health Nurses (CMHNs) towards administering depot medication and issues of compliance and non-compliance. Mental health nurses are frequently perceived as adhering solely to a biomedical approach to patient care in their practice and the therapeutic aspects of their role is frequently unacknowledged. This paper explores how, within the process of giving a depot injection, CMHNs are able to carry out an assessment of their client's needs as well as being someone who is consistent, reliable and supportive. This means that the process of giving a depot injection may be considered as a therapeutic intervention. Qualitative data were obtained through the administration of a semi-structured interview schedule that was constructed and consisted of a range of questions that elicited service users views and opinions related to their experiences of receiving depot neuroleptic medication in the community. The relationship between patient and nurse, as this study reveals, was one that was not only therapeutic, but also provided a forum where psychosocial and clinical issues could be discussed and explored. Crucially, the service users felt they did have a role and an influence in the delivery of their care.
Collapse
|
92
|
Kinders RJ, Hollingshead M, Parchment RE, Khin S, Kaur G, Phillips L, Tomaszewski J, Doroshow J. Preclinical modeling of a phase 0 clinical trial protocol. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.14058] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
14058 Background: The Exploratory IND program initiated at NCI (“Phase 0”) is designed to evaluate the pharmacodynamic effects (PD) of candidate drugs at the molecular level in the clinic. Trials employ patient biopsies and surrogate tissues (e.g. PBMCs) to determine the quantitative effect of the agent on its putative target, after a minimum number of doses. The approach requires repeated biopsy of the tumor, an understanding of the time-effect window, and some knowledge of the dose level likely to cause a measurable drug effect. Methods: Prior to initiating a Phase 0 study of the PARP (PolyAdenosyl-Ribose Polymerase) inhibitor, ABT-888, we developed a pre-clinical model to mirror the clinical protocol. Colo 829 and A375 xenografts in athymic nude [nu/nu (NCr)] mice were examined for time and dose effect on PARP using a validated, quantitative PAR assay. Extracts of entire xenografts, quartered xenografts and 18 gauge needle biopsies were examined for variability of baseline and post-treatment PAR levels. Results were cross-checked with Western analysis for polyADP-Ribose (PAR)-labeled proteins in treated mice. Pharmacokinetics (PK) were modeled using plasma drug levels. Additional studies examined the influence of previous biopsy, contralateral biopsy, vehicle treatment, and general anesthesia on PAR in xenografts. Results: A single dose of ABT-888 produced a significant decrease in intracellular PAR levels that could be measured 2 to 6 hours post-dose. PAR levels and drug effect on PAR levels were not influenced by repeated needle biopsies. Variation across xenografts was random for single and bilateral xenograft animal models in the ABT-888 treated, vehicle- and topotecan-treated control groups. Animal handling and socialization appeared to elevate baseline PAR levels, which could confound analysis of study results. Conclusions: Pre-clinical modeling of a specific Phase 0 clinical protocol for drug effects and biological variability provided valuable insights into the development, refinement, and analysis of the currently-active NCI Phase 0 clinical trial of ABT-888. Animal studies were conducted in an AAALAC approved facility under an approved IACUC protocol. Funded by NCI Contract N01-CO-12400. No significant financial relationships to disclose.
Collapse
|
93
|
Williams K, Jenne J, Sterling L, Phillips L, Nivens C. Genotyping Proves Helpful in Identifying a Potential TB Outbreak in a Community Hospital. Am J Infect Control 2007. [DOI: 10.1016/j.ajic.2007.04.168] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
94
|
Yong TY, Phillips L, Horowitz M, Giles N. Severe hypoglycaemic unawareness in a patient with insulinoma. Intern Med J 2007; 37:141-2. [PMID: 17229264 DOI: 10.1111/j.1445-5994.2007.01255.x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
|
95
|
McCall P, Dunkley S, Lindeman R, Brereton J, Cameron P, Phillips L. THE USE OF RECOMBINANT ACTIVATED FACTOR VII IN CARDIAC SURGERY PATIENTS. Heart Lung Circ 2007. [DOI: 10.1016/j.hlc.2007.02.051] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
96
|
Patik M, Phillips L, Kladny B, Captain A, Gettig E, Krishnamurti L. Structured telephone-based outreach using nonmedical personnel can improve adherence to comprehensive care in families of children with sickle cell disease. Am J Hematol 2006; 81:462-4. [PMID: 16680738 DOI: 10.1002/ajh.20605] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Comprehensive medical care of patients with sickle cell disease decreases morbidity, mortality, and health care resource utilization. Nonadherence to comprehensive care is a barrier to further improvement in the outcomes of these patients. We investigated the feasibility and acceptability of telephone-delivered structured follow-up, support, and education provided by nonmedical personnel and its impact on adherence to comprehensive measures. A semistructured script was designed that included a series of questions relating to the patient's well-being and health-related behaviors and was administered by a graduate student researcher in genetics. Families of all 202 children followed at Children's Hospital of Pittsburgh were attempted to be contacted at 3 monthly intervals from their last contact. A total of 76% [147] of those called were available and willing to talk. Eighteen months after initiation of the study, the number of patients who had not attended comprehensive care clinic for 2 years or more decreased from 46 (19.7%) to 23 patients (9.9%) (P = 0.0019). Similarly, the proportion of eligible patients who had undergone transcranial Doppler screening within the past 12 months increased from 34 to 49% (P = 0.0501). Structured telephone-based follow-up is feasible and well accepted and can lead to improved adherence with comprehensive care measures.
Collapse
|
97
|
Hota BN, Pur S, Phillips L, Weinstein RA, Segreti J. Impact of a fluoroquinolone formulary change on acquisition of quinolone-resistant gram-negative bacilli. Eur J Clin Microbiol Infect Dis 2005; 24:405-10. [PMID: 15931454 DOI: 10.1007/s10096-005-1344-4] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
Rising rates of fluoroquinolone resistance in bacteria have been associated with increased fluoroquinolone use. In vitro data show differences in potency among fluoroquinolone antibiotics against gram-negative bacteria and have led to the hypothesis that rates of selection of resistant microorganisms may be affected by the choice of the specific fluoroquinolone. Because clinical data to prove this hypothesis are lacking, the aim of the present study was to determine rates of acquisition of quinolone-resistant gram-negative bacilli (QRGNB) in the fecal flora of medical intensive care unit patients before and after a formulary change from ciprofloxacin to levofloxacin. Unadjusted rate ratios for acquisition of QRGNB were 1.09 (95%CI, 1.02-1.16) for each day of ciprofloxacin use and 1.01 (95%CI, 0.87-1.17) for each day of levofloxacin use. Following adjustment for other antibiotic use, enteral feeding, APACHE II score, and nursing home admission, neither ciprofloxacin nor levofloxacin use was associated with acquisition of QRGNB. In conclusion, a formulary change from ciprofloxacin to levofloxacin was not significantly associated with an increased risk of acquisition of QRGNB.
Collapse
|
98
|
Fare LR, Actor P, Sachs C, Phillips L, Joloza M, Pauls JF, Weisbach JA. Comparative serum levels and protective activity of parenterally administered cephalosporins in experimental animals. Antimicrob Agents Chemother 2005; 6:150-5. [PMID: 15828185 PMCID: PMC444620 DOI: 10.1128/aac.6.2.150] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Six cephalosporin antibiotics were administered subcutaneously to mice at a level of 20 mg/kg. The serum levels of each were determined at five time intervals ranging from 5 to 120 min after dosing. Urinary recovery and the presence of active metabolites in mouse urine were determined. The peak serum levels and serum half-lives in mice were found to be positively correlated with the mean effective dose values obtained after lethal challenge with Escherichia coli. The administration of cefazolin and cephanone resulted in the highest serum level and the best protection. Good protection was obtained with cephaloridine despite somewhat lower serum levels. The cephalosporins with the acetoxy side chain (cephalothin, cephapirin, and cephacetrile) showed lower serum levels and the poorest protection. Cefazolin, cephaloridine, and cephalothin serum levels were also determined in dogs, squirrel monkeys, and rabbits. A mixed response was obtained in these species, with cefazolin peak serum levels being highest in rabbits and cephaloridine peak highest in dogs.
Collapse
|
99
|
Menneer T, Barrett DJ, Phillips L, Donnelly N, Cave KR. The effect of training on search for complex stimuli. J Vis 2004. [DOI: 10.1167/4.8.338] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
100
|
Hopkins T, Neighbors R, Strickler P, Phillips L. Notes- Some 4-Halo-2-butynyl N-Substituted Carbamates. J Org Chem 2003. [DOI: 10.1021/jo01094a618] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|